AVITA Therapeutics, Inc. — Form 8-K Summary
Reporting date: December 1, 2020. The filing reports the appointment of Kathy McGee as Chief Operating Officer and the related executive employment agreement. The registrant is identified in the filing as Avita Therapeutics, Inc.; the requested company metadata identifies AVITA Medical, Inc.
Business Context and Reporting Period
This is a current report under Items 1.01 and 5.02 concerning a material employment agreement and the appointment of a senior executive. It is not a periodic financial report and does not provide quarterly or annual operating results.
Financial and Operating Metrics
- No revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet figures are provided.
- Ms. McGee will receive an annual base salary of $345,000, subject to customary deductions and annual Board review.
- She is eligible for an annual performance bonus equal to 30% of base salary, subject to performance targets and continued employment requirements. For 2020, the potential bonus is prorated based on salary earned during the year.
- She will receive a taxable $25,000 relocation payment, subject to reimbursement if she does not relocate to the Los Angeles area within the specified timeframe after the Company announces a return-to-work date.
- Subject to Board approval, she may receive options for up to 128,000 common shares.
Material Changes Versus the Prior Comparable Period
- Effective December 1, 2020, Kathy McGee was appointed Chief Operating Officer.
- The filing does not provide a prior-period financial comparison or quantify the impact of the appointment on results.
Agreement Terms, Outlook, and Risks
- The employment agreement has no specified term and is at-will.
- The potential equity award consists of 95,000 options vesting upon achievement of established performance metrics and 33,000 options vesting at 8,250 options per year over four years, beginning after the first year of service.
- Any equity grant is subject to Board approval, the Company’s 2020 Omnibus Incentive Plan, and a separate Share Option Agreement.
- The agreement includes continued-employment conditions for eligibility to receive the annual bonus.
- The filing provides no broader financial guidance, operating outlook, liquidity forecast, or identified contingencies beyond the employment-related terms.
Important Facts for Investors to Verify
- Whether the proposed 128,000-share option award was approved and the final exercise price and grant date.
- The performance metrics applicable to the 95,000 performance-based options and the annual bonus.
- The accounting and cash impact of the $345,000 salary, potential bonus, relocation payment, and equity compensation.
- The Company’s current corporate name and whether the historical “Avita Therapeutics” name has been changed to AVITA Medical.
- Subsequent filings for any changes to Ms. McGee’s employment, compensation, or option awards.